Neonatal BCG Vaccination Reduces Interferon-γ Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled Trial

Bridget Freyne, Nicole L. Messina, Susan Donath, Susie Germano, Rhian Bonnici, Kaya Gardiner, Dan Casalaz, Roy M. Robins-Browne, Mihai G. Netea, Katie L. Flanagan, Toby Kollmann, and Nigel Curtis; for the Melbourne Infant Study: BCG for Allergy and Infection Reduction

Background. BCG vaccination has beneficial non-specific (heterologous) effects that protect against nonmycobacterial infections. We have previously reported that BCG vaccination at birth alters in vitro cytokine responses to heterologous stimulants in the neonatal period. This study investigated heterologous responses in 167 infants in the same trial 7 months after randomization.

Methods. A whole-blood assay was used to interrogate in vitro cytokine responses to heterologous stimulants (killed pathogens) and Toll-like receptor (TLR) ligands.

Results. Compared to BCG-naive infants, BCG-vaccinated infants had increased production of interferon gamma (IFN-γ) and monokine induced by gamma interferon (MIG) in response to mycobacterial stimulation and decreased production of IFN-γ in response to heterologous stimulation and TLR ligands. Reduced IFN-γ responses were attributable to a decrease in the proportion of infants who mounted a detectable IFN-γ response. BCG-vaccinated infants also had increased production of MIG and interleukin-8 (IL-8), and decreased production of IL-10, macrophage inflammatory protein-1α (MIP-1α), and MIP-1β, the pattern of which varied by stimulant. IL-1Ra responses following TLR1/2 (Pam3CYSK4) stimulation were increased in BCG-vaccinated infants. Both sex and maternal BCG vaccination status influenced the effect of neonatal BCG vaccination.

Conclusions. BCG vaccination leads to changes in IFN-γ responsiveness to heterologous stimulation. BCG-induced changes in other cytokine responses to heterologous stimulation vary by pathogen.

Keywords: BCG; immunization; heterologous; non-specific effects; innate immunity; infants

BCG vaccination at birth is associated with decreased mortality in infants [1, 2]. This is proposed to be due to heterologous ("off-target" or "non-specific") protection against early-life infections, an effect thought to result from the immunomodulatory properties of BCG [3, 4]. The beneficial non-specific effects of BCG vaccine persist beyond the neonatal period. BCG vaccination leads to changes in IFN-γ responsiveness to heterologous stimulation and Toll-like receptor (TLR) ligands.

The mechanisms underlying the beneficial heterologous effects of BCG vaccination remain unclear [10]. We have previously shown that in vitro cytokine responses to heterologous stimulants differ between BCG-vaccinated and BCG-naive neonates [11]. The longer-term heterologous immunological effects induced by neonatal BCG are poorly defined but are likely to be different. Maturational changes mean the immune response in infancy is different to that of neonates [12–14]. In addition, a central hypothesis in the literature on the non-specific effects of vaccination is that live vaccines confer protection against all-cause mortality, which is negated by subsequent nonlive vaccines in the first 6 months of life [15]. In the current study, we report the effect of neonatal BCG vaccination on heterologous cytokine

Received 5 September 2019; editorial decision 10 January 2020; accepted 27 January 2020.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, redistribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1093/infdis/jiaa030
responses in infants from a randomized controlled trial at 7 months of age.

**METHODS**

Participants were a subset of infants recruited from the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), in which neonates were randomized to vaccination with BCG-Denmark 0.05 mL intradermally or no BCG vaccination (ClinicalTrials.gov identifier NCT01906853). The inclusion and exclusion criteria for MIS BAIR are described elsewhere [16]. MIS BAIR participants were invited to attend a 7-month study visit to provide a blood sample. All participants with a blood sample from December 2014 to April 2016 were recruited to this substudy. Inclusion criteria for cytokine analysis were as follows: (1) sufficient blood for all stimulants, or (2) participant provided sample in previous study [11]. Exclusion criteria were fever in the previous 24 hours, chronic illness, < 2 doses of the routine scheduled vaccines, any vaccination within the last 7 days, and any blood products since birth (Figure 1).

Venous blood was collected and in vitro stimulation assays were done as described previously [11]. In brief, whole blood, diluted 1:1 with RPMI 1640 medium (GlutaMAX Supplement, HEPES, Gibco, Life Technologies), was stimulated at 37°C (5% carbon dioxide:air) for 20 (± 2) hours with RPMI alone (unstimulated control), BCG-Denmark (Serum Statens Institut, Denmark) 75 μg/mL, killed Mycobacterium tuberculosis 1.0 × 10⁶ colony-forming units (CFU)/mL, Escherichia coli 1.0 × 10⁶ CFU/mL, Haemophilus influenzae type B 1.0 × 10⁶ CFU/mL, Staphylococcus aureus 1.0 × 10⁷ CFU/mL, Streptococcus pneumoniae serotype 15C (nonvaccine serotype) 1.0 × 10⁷ CFU/mL, Listeria monocytogenes 1.0 × 10⁶ CFU/mL, Candida albicans 1.0 × 10⁶ CFU/mL, and the Toll-like receptor (TLR) ligands lipopolysaccharide (LPS; TLR4 agonist) 100 ng/mL, resiquimod (R848; TLR 7/8) 3.5 μg/mL, peptidoglycan (PEPG; TLR 2/4) 10 μg/mL, and (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl) -N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4OH, trihydrochloride (Pam3CSK4; TLR 1/2) 1 μg/mL (all from InvivoGen). When insufficient blood was available for all stimulations, a predetermined priority order was used. The following cytokines were measured in supernatants using an xMAP Luminex 200 Analyser as described previously: interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), IL-1β, macrophage migration inhibitory factor (MIF), IL-8 (CXCL8), monokine induced by gamma interferon (MIG) (CXCL9), interferon-gamma induced protein (IP-10) (CXCL10), monocyte chemoattractant protein-1 (MCP-1) (CCL2), macrophage inflammatory protein-1α (MIP-1α) (CCL3), MIP-1β

![Flow diagram showing participant inclusion. Table shows number of individual stimulations done for each stimulant. Abbreviations: LPS, lipopolysaccharide; PEPG, peptidoglycan; TLR, Toll-like receptor.](image-url)
(CCL4), IL-10, and IL-1Ra [11]. Study staff were blinded to the BCG vaccination status of participants.

Statistical analysis was done using Stata version 13.1 software. Cytokine results below the lower limit of detection were assigned a value of half the lowest detectable value. There were 14 values above the upper limit of detection; these were excluded from the analysis. Proportions of detectable values for each cytokine are shown in Supplementary Table 1.

Prior to analysis, all cytokine data were log-transformed. Regression analyses, with the log-transformed value of the unstimulated cytokine values as a covariate, was used to determine the effect of BCG vaccination, maternal BCG vaccination status, and infants’ sex on cytokine production in response to each stimulant. This approach was used in all regression analyses to account for variability in unstimulated samples and avoids the need for nil subtraction. For cytokine/stimulant pairs with normally distributed data (Supplementary Figure 1), linear regression was used and results are presented as geometric mean ratio (GMR) with 95% confidence interval (CI). For cytokine/stimulant pairs with nonnormally distributed data (Supplementary Figure 1), quantile regression was used and results are presented as differences in the medians with 95% CI.

Subgroup analysis (sex and maternal BCG vaccination status) was done when there was statistical evidence of an interaction between BCG vaccination and the subgroup variable, as determined by interaction analysis (Supplementary Table 4). Given the smaller numbers of participants in subgroup analyses, quantile regression was used, with bootstrapping as required.

Multivariable analysis was done to assess the effect of sex, delivery method, age at infant BCG vaccination (< 48 or ≥ 48 hours of life), maternal BCG vaccination status, age at blood sample, and the number of doses of routine vaccinations received. Multivariable analyses, with the unstimulated values as a covariate, were done using linear or quantile regression as per the corresponding cytokine/stimulant pair in the primary univariate analysis.

For cytokines that showed a dichotomous response, participants were classified according to whether cytokine concentrations in the stimulated supernatants were above (“responders”) or below (“nonresponders”) the lower limit of detection. Fisher exact test was used to compare the proportion of “responders” between BCG-vaccinated and BCG-naive participants. To assess the contribution of this observation to the results of the primary analysis, a sensitivity analyses was done for the effect of BCG vaccination when “nonresponders” were excluded.

The study was approved by the research ethics committees of the Royal Children's Hospital (HREC 33025) and the Mercy Hospital for Women (HREC R12/28).

RESULTS

Demographic features of participants were similar between BCG-vaccinated and BCG-naive participants (Table 1). In unstimulated samples, BCG-vaccinated infants had lower overall cytokine concentrations (particularly IL-10, MIF, IP-10, and IL-8) compared with BCG-naive infants (Table 2). In response to all stimulants, there was marked interindividual variability in cytokine production (Supplementary Figure 1). For IFN-γ, IP-10, IL-1Ra, and IL-1β, there was evidence of dichotomous responses, that is, participants who did or did not mount a measurable cytokine response following stimulation.

In response to the specific mycobacterial antigens BCG and M. tuberculosis, BCG-vaccinated infants had higher production of IFN-γ and MIG compared with BCG-naive infants, and also higher TNF-α and IL-6 following stimulation with BCG (Figure 2 and Supplementary Table 1). In response to heterologous stimulation with the Gram-positive bacteria S. pyogenes and S. aureus, BCG-vaccinated infants had differential production of chemokines including MIF, MIG, and MIP-1β. Chemokine production in response to stimulation with the intracellular pathogens (L. monocytogenes and C. albicans) was also altered in BCG-vaccinated infants (Figure 2 and Supplementary Table 1). In response to stimulation with the Gram-negative bacteria E. coli and H. influenzae, and the TLR agonist LPS, BCG-vaccinated infants had decreased IFN-γ responses and increased IL-8 response compared with BCG-naive infants. In response to stimulation with TLR agonists Pam3CYSK4 (TLR1/2) and PEPG (TLR2), BCG-vaccinated infants had increased IL-1Ra production and decreased IFN-γ production, respectively (Figure 2 and Supplementary Table 1).

There was a dichotomous IFN-γ response to all stimulants aside from R848, with a distinct separation between “responders” and “nonresponders.” For the specific mycobacterial antigens, BCG and M. tuberculosis, there was a higher proportion of IFN-γ responders in the BCG-vaccinated group compared to the BCG-naive group (Figure 3 and Supplementary Table 2). Conversely, for the heterologous stimulants, the proportion of IFN-γ responders was significantly lower in BCG-vaccinated infants for all stimulants with the exception of S. pneumoniae (Figure 3 and Supplementary Table 2). IP-10, IL-1Ra, and IL-1β responses showed a similar pattern; however, differences in the proportion of responders were not statistically significant between BCG-vaccinated and BCG-naive infants (Supplementary Table 2).

A sensitivity analysis done after removal of all nonresponders showed no significant difference in IFN-γ responses to heterologous stimulants between BCG-vaccinated and BCG-naive infants, revealing that the observed difference in IFN-γ GMRs was attributable to the change in proportion of “responders” (Supplementary Table 3). In contrast, the difference in the specific IFN-γ response to in vitro BCG stimulation between BCG-vaccinated and BCG-naive infants was still observed.

Infants’ sex also independently influenced cytokine responses. Compared with girls, boys had increased production
of both MCP-1 and MIP-1β in response to almost all stimulants (Supplementary Table 1 and Supplementary Figure 2). Boys also had increased production of IFN-γ in response to stimulation with BCG, E. coli, H. influenzae, and PEPG, and TNF-α in response to most stimulants, particularly E. coli, H. influenzae, LPS, and R848 (Supplementary Table 1 and Supplementary Figure 2). MIG production was also higher in boys following stimulation with E. coli. Conversely, boys had

| Characteristic                                      | BCG-vaccinated | BCG-naive | Total   |
|-----------------------------------------------------|----------------|-----------|---------|
| All participants                                    | 99 (59.3)      | 68 (40.7) | 167 (100) |
| Sex                                                 |                |           |         |
| Male                                                | 57 (57.6)      | 37 (64.4) | 94 (56.3) |
| Female                                              | 42 (42.4)      | 31 (45.6) | 73 (43.7) |
| Race/ethnicity                                      |                |           |         |
| White                                               | 79 (79.8)      | 57 (83.8) | 136 (81.4) |
| Asian                                               | 4 (4.0)        | 3 (4.4)   | 7 (4.3)   |
| Mixed ethnicity                                     | 4 (4.0)        | 2 (3.0)   | 6 (3.6)   |
| Middle Eastern                                      | 1 (1.0)        | 0 (0.0)   | 1 (0.5)   |
| Missing                                             | 11 (11.2)      | 6 (8.8)   | 17 (10.2) |
| Mode of delivery                                    |                |           |         |
| Vaginal                                             | 63 (63.6)      | 40 (58.8) | 103 (61.7) |
| Cesarean                                            | 36 (36.4)      | 28 (41.2) | 64 (38.3) |
| Maternal BCG vaccination                            |                |           |         |
| Yes                                                 | 21 (21.2)      | 12 (17.7) | 33 (19.8) |
| No                                                  | 73 (73.8)      | 51 (75.0) | 124 (74.2) |
| Unknown                                             | 5 (5.0)        | 5 (7.3)   | 10 (6.0)  |
| Maternal education level                            |                |           |         |
| Completed high school                               | 15 (15.2)      | 8 (11.8)  | 23 (13.8) |
| Trade certificate                                   | 12 (12.1)      | 8 (11.7)  | 20 (12.0) |
| University degree                                   | 48 (48.5)      | 31 (45.6) | 79 (47.3) |
| University higher degree                            | 21 (21.2)      | 18 (26.5) | 39 (23.4) |
| Other                                               | 3 (3.0)        | 3 (4.4)   | 6 (3.6)   |
| No. of other children < 5 y of age in house         |                |           |         |
| 0                                                   | 54 (54.6)      | 45 (66.2) | 99 (59.3) |
| 1                                                   | 36 (36.4)      | 20 (29.4) | 56 (33.5) |
| 2                                                   | 9 (9.1)        | 3 (4.4)   | 12 (7.2)  |
| Participant attends childcare                       |                |           |         |
| Yes                                                 | 7 (7.1)        | 5 (7.4)   | 12 (7.2)  |
| No                                                  | 92 (92.9)      | 63 (92.6) | 155 (92.8) |
| Day of life of BCG vaccination                      |                |           |         |
| Mean (SD)                                           | 2.0 (1.6)      | ...       | ...      |
| Median (IQR)                                        | 1 (0–6)        | ...       | ...      |
| Age at 7-mo blood sample, d                         |                |           |         |
| Mean (SD)                                           | 201 (23.1)     | 200 (22.9) | 201 (23.0) |
| Median (IQR)                                        | 197 (184–223)  | 200 (182–218) | 199 (182–221) |
| Interval between BCG vaccination and 7m blood sample, d |                |           |         |
| Mean (SD)                                           | 199.3 (23.2)   | ...       | ...      |
| Median (IQR)                                        | 196 (161–238)  | ...       | ...      |
| No. of routine immunization doses prior to 7m blood sample |                |           |         |
| 2                                                   | 51 (51.5)      | 34 (50.0) | 85 (50.9) |
| 3                                                   | 47 (47.5)      | 33 (48.5) | 80 (47.9) |
| Not recorded                                        | 1 (1.0)        | 1 (1.5)   | 2 (1.2)  |
| BCG vaccine batch                                   |                |           |         |
| 1                                                   | 5 (5.1)        | ...       | ...      |
| 2                                                   | 85 (85.9)      | ...       | ...      |
| 3                                                   | 9 (9.1)        | ...       | ...      |

Data are shown as No. (%) unless otherwise indicated.
Abbreviations: IQR, interquartile range; SD, standard deviation.
*Routine immunizations: Infanrix Hexa (hepatitis B, diphtheria-tetanus-pertussis, Haemophilus influenzae type B, inactivated poliovirus); Prevenar 13 (13-valent pneumococcal conjugate vaccine); rotavirus (Rotarix or RotaTeq).
Table 2. Univariate Analysis for the Effect of Neonatal BCG Vaccination Versus No BCG Vaccination on Unstimulated Cytokine Levels

| Cytokine | GMR (95% CI) | P-Value |
|----------|--------------|---------|
| IL-10    | 0.59 (0.43–0.81) | .001   |
| TNF-α    | 0.80 (0.60–1.08)  | .14    |
| IL-6     | 0.90 (0.65–1.25)  | .53    |
| MIF      | 0.78 (0.62–0.99)  | .04    |
| MIG      | 0.79 (0.60–1.08)  | .14    |
| IP-10    | 0.64 (0.49–0.88)  | .003   |
| IL-8     | 0.61 (0.41–0.93)  | .02    |
| MIP-1α   | 0.65 (0.41–1.03)  | .06    |
| MIP-1β   | 0.81 (0.57–1.17)  | .26    |
| IL-1Ra   | 0.87 (0.52–1.46)  | .59    |

Results are shown as GMR for normally distributed data and difference in median from group unstimulated cytokine levels to L. monocytogenes; and decreased MIP-1β in response to E. coli and S. pneumoniae (Supplementary Table 1 and Supplementary Figure 3).

A significant interaction between maternal BCG vaccination and infant BCG vaccination was seen for MIG/E. coli, IL-10/BCG, and IFN-γ/S. pneumoniae cytokine/stimulant pairs (Supplementary Table 4). Separate analyses of the effect of BCG in infants of BCG-vaccinated mothers and infants of BCG-naive mothers showed that in the former there was lower production of MIG in response to E. coli and IFN-γ in response to S. pneumoniae, whereas BCG vaccination had no effect on this response in infants of BCG-naive mothers (Figure 4D). Conversely, infants of BCG-vaccinated mothers had higher production of IL-10 in response to stimulation with BCG (Figure 4D).

Multivariable analyses were done to evaluate the potential confounding effect of sex, maternal BCG vaccination status, mode of delivery, age at BCG vaccination, age at blood draw, and number of routine vaccination doses received (Supplementary Table 5). Covariate analysis with these variables did not reveal any meaningful effect on the primary analysis, thus excluding confounding by these variables.

**DISCUSSION**

We previously reported that BCG vaccination at birth led to decreased production of IL-1ra, IL-6, MCP-1, MIP-1α, and MIP-1β in response to heterologous stimulants and TLR ligands in the neonatal period (7 days after randomization) [11]. This study extends these findings to show that BCG-induced changes in cytokine expression following heterologous stimulation are detectable at 7 months of age, characterized by decreased IFN-γ responsiveness in BCG-vaccinated infants.

Our finding that BCG vaccination was associated with an increase in IFN-γ and proinflammatory cytokines (IL-6, IL-1β, and TNF-α) in response to mycobacterial antigens (BCG and M. tuberculosis) is consistent with prior studies [13, 14, 17–19]. Furthermore, our finding that two-thirds of BCG-naive infants produced IFN-γ in response to in vitro stimulation with BCG supports our previous finding of a role for natural killer cells and unconventional T cells in early IFN-γ responses to BCG [20]. Our main finding that neonatal BCG vaccination is associated with a decrease in the proportion of infants who produce IFN-γ in response to heterologous stimulants has not previously been reported.

Nissen et al reported that, in Danish infants at 12 months of age, BCG vaccination did not lead to differential IFN-γ production either in response to ex vivo heterologous bacterial (E. coli, S. pneumoniae, C. albicans) or LPS stimulation [21]. However, in that study approximately half of the BCG-vaccinated participants did not have a specific IFN-γ response to in vitro BCG stimulation. Smith et al also assessed the effects of BCG on in vitro heterologous cytokine responses in infants, although...
BCG was given at 6 weeks of age [22]. As in our study, BCG-vaccinated infants had an increase in *M. tuberculosis* lysate-induced IFN-γ response. Although there was no significant difference between BCG-vaccinated and BCG-naive infants in IFN-γ production following *E. coli, S. aureus, C. albicans*, LPS, or Pam3CYSK4 stimulation, fold-change analysis showed decreased LPS-induced IFN-γ responses in BCG-vaccinated infants, an effect that did not reach statistical significance given the small sample size.

Compared to BCG-naive infants, BCG-vaccinated infants in our study showed a distinctive pattern of differential chemokine production that varied between biologically related stimulants. Specifically, in response to mycobacterial, Gram-positive, and intracellular heterologous stimuli, chemokine production in BCG-vaccinated infants was characterized by increased production of MIG and a concomitant decrease in MIP-1α and MIP-1β. MIG is produced by activated monocytes and is the primary chemoattractant for T-helper type 1 cells, which are central to the IFN-γ-dependent proinflammatory response to intracellular bacteria and parasites, and has been recently reported to represent a marker of trained immunity after BCG vaccination [23]. In response to Gram-negative bacteria and LPS, BCG-vaccinated infants had increased IL-8 production. IL-8 is central in the innate response to bacterial infection by promoting neutrophil chemotaxis and macrophage activation. Smith et al
Figure 3. Proportion of BCG-vaccinated and BCG-naive participants with production of interferon gamma (IFN-γ) in response to heterologous stimulation ("responders") (Fisher exact test). Data for R848 are not included as IFN-γ responses were above the lower limit of detection for all participants.

reported that, as in our study, BCG-vaccinated infants had significantly higher IL-8 production following stimulation with LPS compared to BCG-naive infants [22]. It remains to be seen whether variable “pathogen-specific” in vitro patterns of innate immune response following BCG vaccination correlate with clinical protection.

For the majority of heterologous stimulants, IFN-γ responses in our study were characterized by a significantly lower proportion of IFN-γ responders in the BCG-vaccinated group, which was responsible for the lower IFN-γ GMR in these infants compared to BCG-naive infants. Variable production of IFN-γ by individuals and between populations is well described [13, 19, 24]. This variability in individual IFN-γ responsiveness, which may be genetically or environmentally determined [25, 26], is a potential modifier of the response to BCG. In a group of BCG-naive, tuberculosis skin test–negative adult volunteers in the Netherlands who received BCG vaccination, “nonresponders” were classified as individuals with no IFN-γ response to purified protein derivative and expression of CD8+ regulatory T cells, which persisted up to 1 year postvaccination [27]. Fletcher et al reported differential immune responses following BCG vaccination in infants characterized by differences in monocyte:T-cell ratios and an alternatively activated macrophage phenotype (M2) [28]. More recently, Walk et al reported 2 distinct patterns of immune response to human malaria challenge in BCG-vaccinated volunteers. A subgroup of volunteers with strong monocyte and lymphocyte activation were also characterized by increased IFN-γ, granzyme-B production, and C-reactive protein production [29]. This study is the first to report significant changes in IFN-γ responsiveness in the context of BCG-induced heterologous immunity in infants.

IP-10, IL-1Ra, and IL-1β were the only other cytokines that had a subgroup of nonresponders. This is notable in light of the functional relationship of these cytokines to IFN-γ and their role in the control of inflammation and pathogen persistence following mycobacterial infection [30, 31]. The IL-1 signaling axis is central in mediating the response to BCG vaccination in the setting of both mycobacterial and heterologous infections, and IL-1β is a crucial component for the induction of trained immunity [23, 32–34]. However, in our study the proportion of IL-1Ra and IL-1β responders was not significantly different between BCG-vaccinated and BCG-naive infants. Moreover, sensitivity analysis confirmed that increased IL-1Ra responses following stimulation of TLR 1/2 (Pam3CYSK4)
seen in BCG-vaccinated infants was unaffected by removal of “nonresponders” from the analysis.

In our previous study, we found that infant sex influenced the effect of BCG vaccination on the production of MIF following heterologous stimulation [11]. In the present study, we observed enhanced E. coli, H. influenzae, LPS, and R848-induced production of the macrophage derived proinflammatory cytokines IL-6 and IL-1β in BCG-vaccinated girls (in contrast to boys). This is interesting in light of the suggestion that during the neonatal period, the beneficial effects of BCG vaccination on mortality is stronger in boys [35].

Maternal BCG vaccination status is associated with increased BCG scar formation and decreased all-cause mortality in BCG-vaccinated infants [8]. Mawa et al reported altered cytokine responses to TLR ligands, including LPS, in the cord blood of infants of BCG-vaccinated mothers [36]. Our finding that infants of BCG-vaccinated mothers had altered cytokine production following heterologous stimulation, independent of infant BCG vaccination status, raises the possibility that maternal BCG vaccination “primes” the response to infant BCG vaccination. Furthermore, an interaction between maternal and infant BCG vaccination on IFN-γ production in response to S. pneumoniae.

Figure 4. Subgroup analysis for the effect of infant sex and maternal BCG vaccination on in vitro cytokine responses. Interleukin 6 (A), interleukin 1β (B), and remaining cytokine/stimulant pairs (C) with a significant interaction between sex and BCG vaccination. Geometric mean ratios (GMRs) and 95% confidence intervals (CIs) are shown for the effect of infant BCG vaccination on all study participants (i), girls (ii), and boys (iii). D, Cytokine/stimulant pairs with a significant interaction between maternal BCG vaccination and BCG vaccination. GMRs and 95% CIs are shown for the effect of infant BCG vaccination on all study participants (i), infants whose mothers were BCG-vaccinated (ii), and infants whose mothers were BCG naive (iii). GMR > 1 indicates that cytokine production is higher in BCG-vaccinated infants. Abbreviations: CI, confidence interval; GMR, geometric mean ratio; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MIG, monokine induced by gamma interferon; MIP, macrophage inflammatory protein; PEPG, peptidoglycan; TNF, tumor necrosis factor.
was also found in our previous study; however, maternal BCG had the opposite effect at this time point [11]. This finding is particularly intriguing in light of the finding that BCG vaccine protects infants against respiratory infections only in infants whose mothers were also BCG vaccinated [9, 37].

There is longstanding interest in the variability of BCG vaccine efficacy against tuberculosis infection in different geographic locations. To date, clinically significant heterologous effects of BCG have mainly been documented in African populations [35]. Following BCG vaccination, infant cytokine responses to mycobacteria differ between African and European populations; however, it remains uncertain whether this is due to genetic or environmental influences [13, 14, 38]. In this study, the majority of participants were white, precluding subgroup analysis by ethnicity. Exposure to environmental mycobacteria and chronic helminth infection has been associated with altered BCG-induced IFN-γ production in some populations [38]. It is unlikely that exposure to infection was a confounder in our study, as proxy measures of exposure to common childhood infections (attendance at childcare and number of children aged < 5 years in the household) were similar between groups.

The strengths of this study include its large sample size and the use of samples from participants from a randomized controlled trial. The use of a large number of stimulants and multiplex cytokine analysis enabled a comprehensive interrogation of the immune response. In addition, we used multivariable analysis to identify potential confounders and a highly standardized laboratory protocol to reduce variation. Furthermore, we used the unstimulated sample as a covariate to control for interindividual variability in cytokine responses. A sensitivity analysis, excluding the use of unstimulated samples as a covariate in samples where there was an independent effect on the constitutive expression of a cytokine, showed that this did not lead to overcorrection (data not shown). Our study also has several limitations that are common to research of this type. First, for some cytokine/stimulant pairs, there were lower numbers of participants from whom samples were available. However, this is a large study and our statistical analysis accounted for the varying distributions of individual cytokine/stimulant pair data. Second, while we tested for several potential confounders selected due to their biological plausibility and previously published data, it is possible there are others that may have influenced our findings. Third, there was a risk of type I error due to multiple comparisons. Statistical correction for multiple comparisons was not done as this was an exploratory analysis that aimed to find consistent patterns in BCG-induced alterations in cytokine responses. In addition, we have shown all analyses in their entirety to aid interpretation of the results in context. Finally, routine vaccines from the Australian immunization schedule differ to those administered in low- and middle-income countries.

In summary, at 7 months of age, following neonatal BCG vaccination, infants had lower IFN-γ responses to heterologous stimulants and TLR ligands compared with BCG-naive infants. This resulted from a reduction in the proportion of infants who responded by producing IFN-γ rather than a reduced level of IFN-γ production by all participants. This study is the first to report divergent IFN-γ responses between mycobacterial and heterologous stimulation following BCG vaccination. BCG vaccination is associated with variable patterns of chemokine response depending on the stimulating pathogen. There was a significant interaction between both sex and maternal BCG vaccination with neonatal BCG vaccine-induced responses. Relating the immunological effects of BCG observed among in vitro studies with clinical outcome should be a priority for future research.

Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes
Acknowledgments. The authors thank Judith Spotswood for collection of blood samples; Pedro Ramos for help with processing of blood samples; Casey Goodall for help with data entry; and Dr Laure Pittet for her helpful comments on the manuscript.

Financial support. This work was supported by the National Health and Medical Research Council of Australia (NHMRC) (grant numbers GNT1051228 and GNT1099680); the University of Melbourne (International Research Scholarship to B. F.); the European Society of Paediatric Infectious Diseases (fellowship to B. F.); and the Clifford Craig Foundation. M. G. N. was supported by a Spinoza grant of The Netherlands Organization for Scientific Research.

Potential conflicts of interest. All authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

REFERENCES
1. Higgins JP, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 2016; 355:i5170.
2. Pollard AJ, Finn A, Curtis N. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child 2017; 102:1077–81.
3. Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245–52.

4. Biering-Sørensen S, Aaby P, Napirna BM, et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 2012; 31:306–8.

5. Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among bacille Calmette-Guérin (BCG)-vaccinated children. Pediatrics 2014; 133:e73–81.

6. de Castro MJ, Pardo-Seco J, Martínón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis 2015; 60:1611–9.

7. Thøstesen LM, Kjærgaard J, Pihl GT, et al. Neonatal BCG vaccination and atopic dermatitis before 13 months of age: a randomized clinical trial. Allergy 2018; 73:498–504.

8. Berendsen MLT, Oland CB, Bles P, et al. Maternal priming: bacillus Calmette-Guérin (BCG) vaccine scarring in mothers enhances the survival of their child with a BCG vaccine scar. J Pediatric Infect Dis Soc 2019. doi:10.1093/jpids/piy142.

9. Kjærgaard J, Birk NM, Nissen TN, et al. Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res 2016; 80:681–5.

10. Kandasamy R, Voysey M, McQuaid F, et al. Non-specific immunological effects of selected routine childhood immunisations: systematic review. BMJ 2016; 355:i5225.

11. Freyne B, Donath S, Germano S, et al. Neonatal BCG vaccination influences cytokine responses to Toll-like receptor ligands and heterologous antigens. J Infect Dis 2018; 217:1798–808.

12. Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2014; 6:152–8.

13. Larol MK, Floyd S, Gorak-Stolinska P, et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis 2011; 204:1075–85.

14. Larol MK, Smith SG, Floyd S, et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 2010; 28:1635–41.

15. Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O; OptImmunize Network. Heterologous (“nonspecific”) and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms. Clin Infect Dis 2013; 57:283–9.

16. Messina NL, Gardiner K, Donath S, et al. Study protocol for the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), a randomised controlled trial to determine the non-specific effects of neonatal BCG vaccination in a low-mortality setting. BMJ Open 2019; 9:e032844.

17. Burl S, Adetifa UJ, Cox M, et al. Delaying bacillus Calmette-Guérin vaccination from birth to 4 ½ months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 2010; 185:2620–8.

18. Corral-Fernández NE, Cortez-Espinosa N, Salgado-Bustamante M, et al. Induction of transcription factors, miRNAs and cytokines involved in T lymphocyte differentiation in BCG-vaccinated subjects. Mol Immunol 2016; 77:44–51.

19. van den Biggelaar AH, Prescott SL, Roponen M, et al. Neonatal innate cytokine responses to BCG controlling T-cell development vary between populations. J Allergy Clin Immunol 2009; 124:544–50, e1–e2.

20. Zufferey C, Germano S, Dutta B, Ritz N, Curtis N. The contribution of non-conventional T cells and NK cells in the mycobacterial-specific IFNγ response in bacille Calmette-Guérin (BCG)-immunized infants. PLoS One 2013; 8:e77334.

21. Nissen TN, Birk NM, Blok BA, et al. Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial. Eur J Clin Microbiol Infect Dis 2018; 37:29–41.

22. Smith SG, Kleinnijenhuis J, Netea MG, Dockrell HM. Whole blood profiling of bacillus Calmette-Guérin-induced trained innate immunity in infants identifies epidermal growth factor, IL-6, platelet-derived growth factor-AB/BB, and natural killer cell activation. Front Immunol 2017; 8:644.

23. Joosten SA, van Meijgaard KE, Arend SM, et al. Mycobacterial growth inhibition is associated with trained innate immunity. J Clin Invest 2018; 128:1837–51.

24. Djuardi Y, Sartono E, Wibowo H, Supali T, Yazdanbakhsh M. A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses. PLoS One 2010; 5:e14066.

25. Finan C, Ota MO, Marchant A, Newport MJ. Natural variation in immune responses to neonatal Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination in a cohort of Gambian infants. PLoS One 2008; 3:e3485.

26. Newport MJ, Goetzhebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A; MRC Gambia Twin Study Group. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004; 5:122–9.

27. Boer MC, Prins C, van Meijgaard KE, van Dissel JT, Ottenhoff TH, Joosten SA. Mycobacterium bovis BCG vaccination induces divergent proinflammatory or regulatory T cell responses in adults. Clin Vaccine Immunol 2015; 22:778–88.
28. Fletcher HA, Filali-Mouhim A, Nemes E, et al; BCG Study Team. Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study. BMC Med 2016; 14:76.

29. Walk J, de Bree LCJ, Graumans W, et al. Outcomes of controlled human malaria infection after BCG vaccination. Nat Commun 2019; 10:874.

30. Bohrer AC, Tocheny C, Assmann M, Ganusov VV, Mayer-Barber KD. Cutting Edge: IL-1R1 mediates host resistance to Mycobacterium tuberculosis by trans-protection of infected cells. J Immunol 2018; 201:1645–50.

31. Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014; 511:99–103.

32. Arts RJW, Moorlag S, Novakovic B, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 2018; 23:89–100.e5.

33. Koeken VACM, Verrall AJ, Netea MG, Hill PC, van Crevel R. Trained innate immunity and resistance to Mycobacterium tuberculosis infection. Clin Microbiol Infect 2019; 25:1468–72.

34. Moorlag SJCFM, Röring RJ, Joosten LAB, Netea MG. The role of the interleukin-1 family in trained immunity. Immunol Rev 2018; 281:28–39.

35. Biering-Sørensen S, Jensen KJ, Monterio I, Ravn H, Aaby P, Benn CS. Rapid protective effects of early BCG on neonatal mortality among low birth weight boys: observations from randomized trials. J Infect Dis 2018; 217:759–66.

36. Mawa PA, Webb EL, Filali-Mouhim A, et al. Maternal BCG scar is associated with increased infant proinflammatory immune responses. Vaccine 2017; 35:273–82.

37. Stensballe LG, Ravn H, Birk NM, et al. BCG vaccination at birth and rate of hospitalization for infection until 15 months of age in Danish children: a randomized clinical multicenter trial. J Pediatr Infect Dis Soc 2019; 8:213–20.

38. Weir RE, Black GF, Nazareth B, et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi. Clin Exp Immunol 2006; 146:390–9.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Freyne, B; Messina, NL; Donath, S; Germano, S; Bonnici, R; Gardiner, K; Casalaz, D; Robins-Browne, RM; Netea, MG; Flanagan, KL; Kollmann, T; Curtis, N

Title:
Neonatal BCG Vaccination Reduces Interferon-gamma Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled

Date:
2020-06-15

Citation:
Freyne, B., Messina, N. L., Donath, S., Germano, S., Bonnici, R., Gardiner, K., Casalaz, D., Robins-Browne, R. M., Netea, M. G., Flanagan, K. L., Kollmann, T. & Curtis, N. (2020). Neonatal BCG Vaccination Reduces Interferon-gamma Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled. JOURNAL OF INFECTIOUS DISEASES, 221 (12), pp.1999-2009. https://doi.org/10.1093/infdis/jiaa030.

Persistent Link:
http://hdl.handle.net/11343/245445

File Description:
published version

License:
CC BY